10-K: Corteva Reports Strong 2025 Growth, Plans Dual Spin-Off

Corteva, Inc. reported a 3% increase in net sales and a 14% rise in operating EBITDA for 2025, while announcing plans to separate its Seed and Crop Protection businesses into two independent public companies.

Summary

• Net sales for 2025 increased by 3% to $17,401 million, driven by a 3% increase in volume and a 1% increase in price, partially offset by a 1% unfavorable currency impact.
• Operating EBITDA grew by 14% to $3,848 million in 2025, primarily due to volume growth, favorable Seed price and product mix, ongoing cost and productivity benefits, and net royalty improvement.
• Income from continuing operations after income taxes was $1,204 million in 2025, up from $863 million in 2024.
• Cost of goods sold decreased to $9,172 million (53% of net sales) in 2025 from $9,529 million (56% of net sales) in 2024, attributed to cost actions, raw material deflation, and lower commodity prices.
• The company returned approximately $1.5 billion to shareholders in 2025 through share repurchases and common stock dividends.
• The Board of Directors approved a 6% increase in the quarterly common stock dividend, raising it to $0.18 per share, effective July 29, 2025.
• Corteva announced its intent on October 1, 2025, to separate its Seed and Crop Protection businesses into two standalone, publicly traded companies via a tax-free spin-off for U.S. federal income tax purposes.
• A $610 million charge was recorded in 2025 relating to the resolution of litigation with Bayer, which included the termination or amendment of related licenses and new cotton licensing arrangements.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, highlighting strong financial performance, strategic initiatives like the planned spin-off, and significant shareholder returns, despite ongoing litigation and currency headwinds.

Positives

• Net sales increased by 3% to $17,401 million in 2025, driven by 3% volume growth and 1% price increases.
• Operating EBITDA grew significantly by 14% to $3,848 million in 2025, reflecting strong commercial execution and cost management.
• Cost of goods sold decreased to 53% of net sales in 2025 from 56% in 2024, indicating improved cost and productivity actions, raw material deflation, and lower commodity prices.
• Income from continuing operations after income taxes rose substantially to $1,204 million in 2025 from $863 million in 2024.
• The Seed segment's net sales increased 4% to $9,898 million, with operating EBITDA up 19% to $2,636 million, and a segment operating EBITDA margin improvement of approximately 340 basis points.
• The Crop Protection segment's net sales increased 2% to $7,503 million, with operating EBITDA up 6% to $1,350 million, and a segment operating EBITDA margin improvement of approximately 70 basis points.
• The company returned approximately $1.5 billion to shareholders in 2025 through share repurchases and common stock dividends.
• The quarterly common stock dividend was increased by 6% to $0.18 per share.
• Free Cash Flow saw a substantial increase to $2,866 million in 2025 from $1,699 million in 2024.
• The company successfully resolved outstanding litigation with Bayer, including the termination or amendment of related licenses, which supports product out-licensing growth in competitive markets.

Negatives

• An unfavorable currency impact of 1% partially offset net sales growth in 2025.
• Crop Protection pricing declined primarily due to challenging market dynamics in Latin America.
• Other income (expense) net resulted in a higher expense of $(570) million in 2025 compared to $(300) million in 2024, primarily driven by litigation resolution charges and the absence of a one-time indemnification payment received in 2024.
• Income (loss) from discontinued operations after income taxes resulted in a loss of $(99) million in 2025, mainly due to charges related to PFAS environmental remediation activities and the NJ Statewide Settlement.
• Research and development expense increased to $1,474 million in 2025 from $1,402 million in 2024, driven by higher employee compensation, contractor, consulting, and facility costs.
• Selling, general and administrative expenses increased to $3,492 million in 2025 from $3,196 million in 2024, due to higher commissions, variable compensation, bad debt expense, legal support fees, and information technology costs.
• A $132 million charge was recorded in 2025 for the establishment of a valuation allowance against the net deferred tax asset position of a legal entity in Brazil (Crop Protection business).
• The company's long-term and short-term credit ratings from Standard & Poor's, Moody's, and Fitch Ratings all carry a 'Watch Negative' outlook, indicating potential for future downgrades.

Risks

• Inability to obtain or maintain necessary regulatory approvals for seed and crop protection products, restricting sales and reducing R&D returns.
• Lengthy, costly, complex, and unpredictable regulatory approval processes, especially for novel technologies, which can reduce return on R&D investments.
• Public understanding and acceptance of biotechnology and agricultural products can affect sales, regulatory requirements, and reputation, potentially leading to litigation or product discontinuation.
• Intensifying competition and industry consolidation, along with the expiration of patent protection, could lead to price pressures and loss of market share.
• Changes in agricultural and related government policies, including reduced subsidies, may negatively impact farmer purchasing power and demand for products.
• Costs of complying with evolving environmental laws and regulations, including those related to PFAS and other substances, could result in significant unanticipated costs or liabilities.
• Climate change and unpredictable seasonal/weather factors can adversely affect demand for crop protection products, seed quality, volume, and cost.
• Funding and staff reductions at U.S. government agencies (EPA, USDA, FDA, HHS) could hinder timely regulatory approvals.
• Competitors successfully establishing intermediary platforms for product distribution could disrupt Corteva's direct sales model.
• Disruptions in the global economy due to geopolitical and military conflicts (e.g., Russia-Ukraine, China-Taiwan tensions) could lead to cyberattacks, supply chain disruptions, and foreign exchange volatility.
• Volatility in input costs (raw materials, production costs) could significantly impact financial results if not fully offset by price increases or productivity improvements.
• Risks associated with international operations, including foreign currency exchange rate fluctuations, inflation, exchange controls, political instability, and trade restrictions.
• Industrial espionage and other disruptions to supply chain, information technology, or network systems, including cyberattacks, could lead to misuse of assets, business disruptions, and loss of intellectual property.
• Significant environmental, litigation, and other commitments and contingencies, including substantial costs and liabilities from past operations and divested businesses (e.g., PFOA, PFAS).
• Dependence on third parties for raw materials, biotechnology trait licenses, and commercialization, with risks of non-performance or disruption.
• Customers' inability to pay their debts to Corteva, especially in economic downturns or adverse growing conditions, could adversely affect results.
• Failure to effectively manage acquisitions, divestitures, strategic investments, and restructurings may prevent the achievement of anticipated benefits or result in asset impairment charges.
• Inability to raise capital through capital markets or short-term debt borrowings could impair liquidity.
• Increases in pension and other post-employment benefit plan funding obligations may adversely affect results of operations, liquidity, or financial condition.
• Global or regional health pandemics or epidemics could negatively impact supply chain, operations, customer demand, and financial results.
• Negative sentiment towards sustainability matters could adversely affect stock price, results of operations, and access to capital.
• Challenges in enforcing intellectual property rights or defending against claims asserted by others (e.g., Inari disputes) could materially affect business and R&D investment returns.
• The availability of counterfeit products could adversely impact Corteva's business by causing loss of consumer confidence, lost sales, and increased litigation risk.
• Restrictions under intellectual property cross-license agreements limit Corteva's ability to develop and commercialize certain products and services.
• Potential liabilities arising from state and federal fraudulent conveyance laws related to the Corteva Separation and related transactions.
• Continuing contingent tax-related liabilities of DowDuPont following the Distribution.
• Risks related to the proposed separation of Seed and Crop Protection businesses, including potential delays, failure to achieve intended benefits, increased costs, dis-synergies, and adverse impact on stock price.

Future Outlook

Corteva intends to complete the separation of its Seed and Crop Protection businesses into two standalone, publicly traded companies in the second half of 2026, aiming for a tax-free spin-off. The Seed business plans growth through gene editing, biofuels, hybrid wheat, expanded crop offerings, out-licensing, and mergers and acquisitions. The Crop Protection business will focus on differentiated, sustainable product offerings, including biologicals, operational excellence, and disciplined mergers and acquisitions. The company expects to achieve an estimated $180 million in savings on a run rate basis by 2027 from the Crop Protection Operations Strategy Restructuring Program. Capital expenditures for 2026 are projected to be approximately $600 million, and share repurchases of about $500 million are expected in the first half of 2026. Contributions to pension plans (excluding the principal U.S. plan) are estimated at $40 million, and OPEB plans at $100 million for 2026, with overall long-term employee benefit costs expected to decrease by approximately $50 million. Environmental-related capital projects are estimated at $14 million for 2026. Management believes current liquidity and access to capital markets will be adequate to meet future cash requirements.

Management Comments

• The company will focus on a value creation framework including: (1) the delivery of top tier technology in our prioritized core markets and crops with a continued focus on differentiation and yield advantage; (2) a continued move towards market share gains in Seed trait out-licensing market; (3) operational improvements focused on driving cost and productivity benefits; and (4) completing the intended separation into two industry-leading public companies in the second half of 2026.
• Corteva aims to deliver greater value and productivity to growers through more differentiated and sustainably advantaged solutions, which in turn promise to strengthen global food security and help farmers address the impacts of climate change.
• The company aims to prioritize investment, organic and inorganic growth, and returning cash to shareholders.
• The company believes its management team has the experience necessary to effectively execute its strategy and advance its product pipelines and technology.
• Management believes that the application of these policies on a consistent basis enables the company to provide the users of the financial statements with useful and reliable information about the company's operating results and financial condition.
• Management believes that sufficient liquidity is available in the United States with global operating cash flows, borrowing capacity from existing committed credit facilities, and access to capital markets and commercial paper markets.

Industry Context

StockSavvy.ai notes that Corteva's strategic move to separate its Seed and Crop Protection businesses aligns with a broader industry trend of specialization and unlocking shareholder value by creating focused entities. This could allow each new company to better tailor its R&D, capital allocation, and market strategies to its specific segment, potentially enhancing agility and competitive positioning against diversified giants like Bayer and Syngenta, or specialized players like FMC. The focus on biologicals and gene editing also reflects key innovation areas in modern agriculture, addressing global food security and climate change challenges.

Comparison to Industry Standards

• StockSavvy.ai notes that Corteva's 3% net sales growth and 14% operating EBITDA growth in 2025 indicate solid performance within the agricultural input industry, which is subject to cyclical commodity prices and weather patterns.
• The company's emphasis on 'top tier technology' and 'differentiated, sustainably advantaged solutions' suggests a strategy to compete on innovation and value rather than solely on price, a common approach among leading agricultural technology firms like Bayer (with its Crop Science division) and Syngenta.
• The planned spin-off into two standalone companies is a significant strategic move, comparable to past large-scale separations in the chemical and agricultural sectors, aiming to create more focused and potentially higher-valued entities.

Management Changes

Corporate Governance

Legal Proceedings

• Corteva filed a lawsuit against Inari Agriculture, Inc. and Inari Agriculture. N.V. on September 27, 2023, alleging Plant Variety Protection infringement, indirect patent infringement, breach of contract, and civil conversion related to seed technologies. The trial is expected to begin in the second half of 2026.
• Corteva resolved its outstanding litigation with Bayer as of January 2026, including an agrobacterium cross-license agreement dispute. Corteva agreed to a payment of $610 million and to drop its AAD-1 patent claims against Bayer. New cotton licensing arrangements were agreed upon.
• The Federal Trade Commission (FTC), along with ten state attorneys general, filed a lawsuit on September 29, 2022, against Corteva and another competitor, alleging unfair methods of competition and unlawful monopoly. Several proposed private class action lawsuits were centralized into a multi-district litigation, with trials expected to begin in 2027.
• As of December 31, 2024, there were asserted claims for personal injury against the former Dow Agrosciences LLC, alleging injuries related to chlorpyrifos exposure (Lorsban). An accrual has been established for the estimated resolution of certain claims.
• EIDP has residual liabilities under its 2004 settlement of a West Virginia state court class action (Leach v. EIDP) related to PFOA contamination, requiring continued water treatment and funding for a medical monitoring program.
• In December 2024, defendants reached a settlement of all currently filed and unfiled personal injury cases in the Ohio MDL for $59 million, with Corteva contributing $8 million.
• Approximately 10,100 cases alleging personal injury from the use of aqueous film-forming foams (AFFF) or contamination, including EIDP and Chemours as defendants, are consolidated in a multi-district litigation (SC MDL). The first bellwether personal injury trial is expected to be scheduled for 2026.
• Corteva, EIDP, DuPont, and Chemours entered into a binding agreement in principle on June 1, 2023, to resolve all PFAS drinking water claims of a defined class of U.S. public water systems for $1.185 billion (Nationwide Water District Settlement), which was deemed final in April 2024. Approximately 900 water districts opted out, and Corteva has been served complaints from these opt-outs.
• On August 3, 2025, Corteva, Chemours, and DuPont agreed to a proposed Judicial Consent Order with the State of New Jersey (NJ Statewide Settlement) to resolve claims related to legacy use of various substances, including PFAS, at four former EIDP sites. The settlement includes aggregate cash payments of $875 million (net present value approximately $500 million) over 25 years, allocated per the MOU. Court approval is expected during the first half of 2026.
• EIDP is a defendant in a putative class action (Baker Class Action) in New York related to alleged PFOA releases. A settlement in principle was reached in June 2025 for $22 million, plus $1 million annually for a medical monitoring fund for five years.
• Natural resource damage lawsuits against EIDP, Chemours, and others, claiming PFC contamination, have been filed by attorneys general in 31 states, the District of Columbia, and three U.S. territories. These cases are largely in the discovery phase.
• Four municipalities in the Netherlands filed complaints in April 2021 alleging contamination from PFOA and GenX emissions. The court ruled defendants liable for PFOA emissions during a certain period, and settlement discussions are ongoing.
• Corteva is part of a Facility Response Group addressing remediation needs at the AltEn ethanol plant in Mead, Nebraska, with an accrual established for its estimated voluntary contribution to remedial action plans.
• The California Department of Toxic Substances Control (DTSC) has filed a state court lawsuit challenging whether the Pittsburg plant's high purity water system required a permit pursuant to the RCRA.

Related Party Transactions

• EIDP, a subsidiary of Corteva, is party to a Master In-House Banking Agreement with Corteva and certain consolidated subsidiaries. EIDP earned $38 million in interest income from Corteva, Inc. through Q3 2024. As of Q4 2024, borrowings under this agreement are classified within EIDP's equity due to a change in repayment intent.
• EIDP declared cash dividends of $1,815 million to Corteva, Inc. for 2025 and $1,750 million for 2024. A dividend payable of $133 million from EIDP to Corteva, Inc. existed at December 31, 2025.
• EIDP repaid a related party revolving loan from Corteva, Inc. in Q4 2023, incurring $20 million in interest expense and paying $40 million in interest in 2023.
• EIDP had payables to Corteva, Inc. of $27 million (current) and $154 million (noncurrent) at December 31, 2025, related to Corteva's indemnification liabilities to Dow and DuPont per the Separation Agreements.
• Corteva holds indemnification assets from Chemours ($138 million current, $470 million non-current) and from DuPont and Dow ($104 million current, $263 million non-current) related to legacy liabilities.
• A letter agreement (Qnity Letter Agreement) effective November 1, 2025, affirms DuPont's obligations to Corteva for legacy liabilities allocated to Qnity Electronics, Inc. following its spin-off from DuPont.

Stakeholder Impact

• Shareholders: Potential for increased value from the planned spin-off, benefiting from increased dividends and share repurchase programs. Exposed to risks from ongoing litigation, regulatory changes, and market volatility.
• Employees: Benefit from career development, training, safety programs, and inclusion initiatives. Potential impact from restructuring programs, including severance.
• Customers: Benefit from science-based innovations, technology-based product offerings, and digital solutions aimed at optimizing yield and profitability. Affected by product availability, pricing, and potential trade disruptions.
• Suppliers: Important part of the supply chain, with long-term contracts for raw materials. Exposed to shifts in demand and production capacity constraints.
• Creditors: Impacted by the company's financial health, credit ratings (currently 'Watch Negative'), and ability to meet debt obligations.
• Regulatory Authorities: Company is subject to extensive environmental and product approval regulations, with increasing complexity and scrutiny, particularly regarding GMOs, crop protection products, and PFAS.

Next Steps

• Complete the intended separation of Seed and Crop Protection businesses into two standalone, publicly traded companies in the second half of 2026.
• Continue focusing on execution, delivering top-tier technology, and driving market share gains in Seed trait out-licensing.
• Pursue operational improvements to drive cost and productivity benefits.
• Deliver more differentiated and sustainably advantaged solutions to growers.
• Prioritize investment, organic and inorganic growth, and returning cash to shareholders.
• Evaluate making discretionary contributions to the principal U.S. pension plan in 2026.
• Expected capital expenditures of approximately $600 million in 2026.
• Expected share repurchases of approximately $500 million under the 2024 Share Buyback Plan for the first half of 2026.
• Expected contributions of approximately $40 million to pension plans (other than principal U.S. plan) and $100 million to OPEB plans in 2026.
• Court approval for the NJ Statewide Settlement is expected during the first half of 2026.
• The trial for the Inari disputes is expected to begin in the second half of 2026.
• The first bellwether personal injury trial for AFFF cases is expected to be scheduled for 2026.
• Trials for the FTC lawsuit claims are expected to begin in 2027.

Key Dates

Recommendation

Corteva demonstrates strong operational performance with increased sales and EBITDA, coupled with a clear strategy for shareholder returns through dividends and buybacks. The planned spin-off of its Seed and Crop Protection businesses could unlock significant value by creating more focused entities. However, the 'Watch Negative' credit rating outlook and substantial ongoing environmental and antitrust litigation, particularly related to PFAS and the FTC, introduce considerable uncertainty and potential future liabilities. The resolution of Bayer disputes is positive, but the overall legal landscape remains complex. A 'hold' recommendation is appropriate given the balance of strong operational execution and strategic initiatives against significant legal and regulatory headwinds.

Keywords

Agriculture, Seed, Crop Protection, Biotechnology, Pesticides, Herbicides, Insecticides, Fungicides, Biologicals, Gene Editing, PFAS, PFOA, SEC Filing, 10-K, Financial Results, Spin-off, Share Repurchase, Dividends, Litigation, Environmental Liabilities, Intellectual Property, Supply Chain, Regulatory Approvals, Corteva, CTVA